Maintenance and consolidation therapy in patients with unresectable stage III/IV non-small cell lung cancer

Oncologist

Volumn 15, Issue 10, 2010, Pages 1034-1042

  Thatcher, Nicholas ^a   Heighway, Jim ^b  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b Cancer Communications and Consultancy Ltd   (United Kingdom)

Author keywords

Cancer vaccine; Immunotherapy; Non small cell lung carcinoma; Stage III; Unresectable

Indexed keywords

ANTINEOPLASTIC AGENT; BELAGENPUMATUCEL L; BEVACIZUMAB; CANCER VACCINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; ETOPOSIDE; GEFITINIB; GEMCITABINE; L BLP25 VACCINE; MUCIN 1; NAVELBINE; PACLITAXEL; PEMETREXED; PLACEBO; PLATINUM COMPLEX; TAXANE DERIVATIVE; TRANSFORMING GROWTH FACTOR BETA2; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANTIBODY RESPONSE; ANTINEOPLASTIC ACTIVITY; ANTISENSE THERAPY; ARTICLE; AUTOIMMUNITY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONSOLIDATION THERAPY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FLU LIKE SYNDROME; GENE EXPRESSION; HUMAN; INFECTION; INOPERABLE CANCER; LOW DRUG DOSE; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; THERAPY DELAY; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANCER VACCINES; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 77958550661     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2009-0292     Document Type: Article

References (53)

1. Parkin DM, Bray F, Ferlay J et al. Global cancer statistics, 2002. CACancer J Clin 2005;55: 74-108.
2. Ferlay J, Autier P, Boniol M et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007;18:581-592.
3. Verdecchia A, Francisci S, Brenner H et al. Recent cancer survival in Europe: a 2000 - 02 period analysis of EUROCARE-4 data. Lancet Oncol 2007;8:784-796.
4. D'Addario G, Felip E. Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008;19 Suppl 2:39-40.
5. Groome PA, Bolejack V, Crowley JJ et al. The IASLC Lung Cancer Staging Project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2007;2:694-705.
6. Winton T, Livingston R, Johnson D et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005;352: 2589-2597.
7. Mäkitaro R, Paakko P, Huhti E, et al. Prospective population-based study on the survival of patients with lung cancer. Eur Respir J 2002;19:1087-1092.
8. Goldstraw P. The 7th Edition of TNM in Lung Cancer: what now? J Thorac Oncol 2009;4:671-673.
9. Bunn PA, Jr., Thatcher N. Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Conclusion. The Oncologist 2008;13(suppl 1):37-46.
10. Scagliotti GV, Parikh P, von Pawel J et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapynaive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-3551.
11. Gronberg BH, Bremnes RM, Flotten O et al. Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced nonsmall- cell lung cancer. J Clin Oncol 2009;27:3217-3224.
12. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355: 2542-2550.
13. Pirker R, Pereira JR, Szczesna A et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): An open-label randomised phase III trial. Lancet 2009;373:1525-1531.
14. Lynch TJ, Patel T, Dreisbach L et al. Cetuximab and first-line taxane/ carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol 2010; 28:911-917.
15. Reck M, von Pawel J, Zatloukal P et al. Overall survival with cisplatingemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 2010;21:1804-1809.
16. Pfister DG, Johnson DH, Azzoli CG et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004;22:330-353.
17. Jett JR, Scott WJ, Rivera MP et al. Guidelines on treatment of stage IIIB non-small cell lung cancer. Chest 2003;123:221S-225S.
18. Okawara G, Mackay JA, EvansWK et al. Management of unresected stage III non-small cell lung cancer: a systematic review. J Thorac Oncol 2006; 1:377-393.
19. Gridelli C, Maione P, Rossi A et al. Potential treatment options after firstline chemotherapy for advanced NSCLC: maintenance treatment or early second-line? The Oncologist 2009;14:137-147.
20. Socinski M. Treatment paradigms in advanced non-small-cell lung cancer: the evolving role of maintenance therapy. E -Updates in Lung Cancer: Controversies & Challenges 2009;3. Available at http://www.cancernetwork.com/cme/article/10165/1443666, accessed September 24, 2010.
21. Thatcher N. The place of targeted therapy in the patient management of non-small cell lung cancer. Lung Cancer 2007;57(suppl 2):S18-S23.
22. Fidias PM, Dakhil SR, Lyss AP et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2009;27: 591-598.
23. Ciuleanu T, Brodowicz T, Zielinski C et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-smallcell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009; 374:1432-1440.
24. O'Byrne K, Rodrigues Pereira J, von Pawel J et al. Molecular and clinical biomarkers of outcome with cetuximab: Data from the phase III FLEX study in non-small cell lung cancer (NSCLC) [abstract P-9160]. Eur J Cancer Supplements 2009;7:553.
25. Reck M, von Pawel J, Zatloukal P et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL. J Clin Oncol 2009;27: 1227-1234.
26. Cappuzzo F, Ciuleanu T, Stelmakh L et al. SATURN: A double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC. J Clin Oncol 2009;27(15 suppl):8001.
27. Cappuzzo F, Coudert BP, Wierzbicki R et al. Efficacy and safety of erlotinib as first-line maintenance in NSCLC following non-progression with chemotherapy: results from the phase III SATURN study. J Thorac Oncol 2009;4:S289.
28. Takeda K, Hida T, Sato T et al. Randomized phase III trial of platinumdoublet chemotherapy followed by gefitinib compared with continued platinum- doublet chemotherapy in Japanese patients with advanced non-smallcell lung cancer: results of a west Japan thoracic oncology group trial (WJTOG0203). J Clin Oncol 2010;28:753-760.
29. Miller VA, O'Connor P, Soh C et al. A randomized, double-blind, placebocontrolled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 2009;27(18 suppl):LBA8002.
30. van Meerbeeck JP, Meersschout S, De Pauw R et al. Modern radiotherapy as part of combined modality treatment in locally advanced non-small cell lung cancer: present status and future prospects. The Oncologist 2008;13: 700-708.
31. Gandara DR, Chansky K, Albain KS et al. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504. J Clin Oncol 2003;21: 2004-2010.
32. Hanna N, Neubauer M, Yiannoutsos C et al. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. J Clin Oncol 2008;26:5755-5760.
33. Kelly K, Chansky K, Gaspar LE et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol 2008;26:2450-2456.
34. Waller EK, Ernstoff MS. Modulation of antitumor immune responses by hematopoietic cytokines. Cancer 2003;97:1797-1809.
35. Parmiani G, Russo V, Marrari A et al. Universal and stemness-related tumor antigens: potential use in cancer immunotherapy. Clin Cancer Res 2007;13:5675-5679.
36. Nemunaitis J, Dillman RO, Schwarzenberger PO et al. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense genemodified allogeneic tumor cell vaccine in non-small-cell lung cancer. J Clin Oncol 2006;24:4721-4730.
37. Fakhrai H, Tong A, Nemunaitis J et al. Correlation of immune responses and survival in a phase II study of belagenpumatucel-L in non-small cell lung cancer. J Clin Oncol 2009;27(15 suppl):3013.
38. von Mensdorff-Pouilly S, Snijdewint FG, Verstraeten AA et al. Human MUC1 mucin: a multifaceted glycoprotein. Int J Biol Markers 2000;15: 343-356.
39. Grinstead JS, Koganty RR, Krantz MJ et al. Effect of glycosylation on MUC1 humoral immune recognition: NMR studies of MUC1 glycopeptide-antibody interactions. Biochemistry 2002;41:9946-9961.
40. Sangha R, Butts C. L-BLP25: a peptide vaccine strategy in non small cell lung cancer. Clin Cancer Res 2007;13:s4652-s4654.
41. Guan HH, Budzynski W, Koganty RR et al. Liposomal formulations of synthetic MUC1 peptides: effects of encapsulation versus surface display of peptides on immune responses. Bioconjug Chem 1998;9:451-458.
42. López-Ferrer A, Curull V, Barranco C et al. Mucins as differentiation markers in bronchial epithelium. Squamous cell carcinoma and adenocarcinoma display similar expression patterns. Am J Respir Cell Mol Biol 2001;24: 22-29.
43. Jarrard JA, Linnoila RI, Lee H et al. MUC1 is a novel marker for the type II pneumocyte lineage during lung carcinogenesis. Cancer Res 1998;58: 5582-5589.
44. Guddo F, Giatromanolaki A, Koukourakis MI et al. MUC1 (episialin) expression in non-small cell lung cancer is independent of EGFR and cerbB-2 expression and correlates with poor survival in node positive patients. J Clin Pathol 1998;51:667-671.
45. Khodarev NN, Pitroda SP, Beckett MA et al. MUC1-induced transcriptional programs associated with tumorigenesis predict outcome in breast and lung cancer. Cancer Res 2009;69:2833-2837.
46. Woenckhaus M, Merk J, Stoehr R et al. Prognostic value of FHIT, CTNNB1, and MUC1 expression in non-small cell lung cancer. Hum Pathol 2008;39:126-136.
47. Ohgami A, Tsuda T, Osaki T et al.MUC1mucinmRNAexpression in stage I lung adenocarcinoma and its association with early recurrence. Ann Thorac Surg 1999;67:810-814.
48. Hirasawa Y, Kohno N, Yokoyama A et al. Natural autoantibody to MUC1 is a prognostic indicator for non-small cell lung cancer. Am J Respir Crit Care Med 2000;161:589-594.
49. Palmer M, Parker J, Modi S et al. Phase I study of the BLP25 (MUC1 peptide) liposomal vaccine for active specific immunotherapy in stage IIIB/IV non-small-cell lung cancer. Clin Lung Cancer 2001;3:49-57;discussion 58.
50. North S, Butts C. Vaccination with BLP25 liposome vaccine to treat nonsmall cell lung and prostate cancers. Expert Rev Vaccines 2005;4:249-257.
51. Butts C, Murray N, Maksymiuk A et al. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol 2005;23:6674-6681.
52. Butts C, Maksymiuk A, Goss G et al. A multicentre phase IIB randomized controlled study of BLP25 liposome vaccine (L-BLP25 or Stimuvax) for active specific immunotherapy of non-small cell lung cancer (NSCLC): updated survival analysis: B1-01. J Thorac Oncol 2007;2:S332-S333.
53. Butts C, Anderson H, Maksymiuk A et al. Long-term safety of BLP25 liposome vaccine (L-BLP25) in patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC). J Clin Oncol 2009;27(15 suppl):3055.